This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
by Zacks Equity Research
Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
Implied Volatility Surging for Regeneron (REGN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Regeneron (REGN) stock based on the movements in the options market lately.
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Alnylam Completes Enrollment in Phase III Study of Lumasiran
by Zacks Equity Research
Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.
Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
by Zacks Equity Research
Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
Alnylam Completes Rolling NDA Submission to FDA for Givosiran
by Zacks Equity Research
Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.
Why Is Regeneron (REGN) Down 8.8% Since Last Earnings Report?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options
by Zacks Equity Research
GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate
by Zacks Equity Research
Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portfolio.
Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Phillip Morris (PM) and United Parcel (UPS).
Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
by Zacks Equity Research
Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
Moving Average Crossover Alert: Regeneron Pharmaceuticals
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Pfizer's Eczema Candidate Meets All Goals in Phase III Study
by Zacks Equity Research
Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline updates by the leading biotech companies.
Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion
by Zacks Equity Research
Regeneron's (REGN) Eylea gets FDA approval for label expansion to include patients of all stages with diabetic retinopathy.
Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.
Regeneron (REGN) Stock Down on Earnings, Sales Miss in Q1
by Zacks Equity Research
Regeneron's (REGN) first-quarter performance was dismal with the company missing on both earnings and sales estimates.
Regeneron (REGN) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of -19.38% and -2.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
bluebird's (BLUE) Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
bluebird (BLUE) reports wider-than-expected Q1 loss. Nevertheless, the pipeline progress looks encouraging.
Regeneron (REGN) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter results.
Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week are earnings releases by most leading biotech entities.
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales
by Zacks Equity Research
Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.